Advances of target therapy in hormone-receptor-positive breast cancer
10.3969/j.issn.1000-8179.2017.13.008
- VernacularTitle:激素受体阳性乳腺癌靶向治疗进展
- Author:
Wen XIA
;
Shusen WANG
- Keywords:
hormone-receptor-positive breast cancer;
hormone therapy;
target therapy
- From:
Chinese Journal of Clinical Oncology
2017;44(13):635-639
- CountryChina
- Language:Chinese
-
Abstract:
Hormone therapy is a major treatment option for hormone-receptor-positive (HR+) breast cancer. Resistance to hormone therapy is the major reason for disease recurrence and progression. Recent studies have identified several resistance mechanisms that lead to the estrogen-independent growth of HR+breast cancer and were exploited to develop novel target drugs, including cyclin-de-pendent kinases 4 and 6 (CDK4/6) inhibitor, mammalian target of rapamycin (mTOR) inhibitor, epidermal growth factor receptor family inhibitor, vascular endothelial growth factor inhibitor, histone deacetylase inhibitor, fibroblast growth factor receptor inhibitor, insulin-like growth factor receptor inhibitor, and checkpoint inhibitor. These inhibitors are being developed to block resistance pathways and improve the efficacy of hormonal therapy. Among these drugs, the mTOR inhibitor everolimus and the CDK4/6 inhibitor palbociclib are currently approved in the United States to treat metastatic HR+breast cancer. In this study, we summarize the frontier advances in the combination of hormone and target therapies.
